生长抑素和生长激素联合治疗胰腺炎与单用生长抑素对照研究的Meta分析  

Meta-analysis on combination of growth hormone and somatostain and single somatostain in treatment of patients with severe acute pancreatitis

作　　者：朱良红[1] 李娟[1] 赵国海[1] 

机构地区：[1]皖南医学院弋矶山医院急诊外科,安徽省药物临床评价中心

出　　处：《中国临床药理学与治疗学》2005年第12期1394-1396,共3页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:进一步了解生长抑素和生长激素联合治疗与单用生长抑素治疗胰腺炎的疗效差异.方法:应用Meta分析方法,对6项研究生长抑素和生长激素联合治疗胰腺炎的病死率、并发症进行同质性检验和合并效应量的估计.结果:病死率同质性检验:χ2=3.156,P＞0.05,并发症同质性检验:χ2=1.210,P＞0.05,均具有同质性,可以合并进行分析.病死率合并效应量的估计:OR合并=3.164, R合并95%可信区间为 1.390～7.200,OR合并的检验:P＜0.05,并发症合并效应量估计:OR合并=3.209, R合并95%可信区间为1.747～5.900.结论:生长抑素联合治疗组的病死率低于单用生长抑素治疗组.联合治疗组疗效优于生长抑素单用组.AIM： To explore the difference of efficacy and safety between combination of growth hormone and somatostain and single somatostain in treatment of patients with severe acute pancreatitis. METHODS： The case fatality rates and complication incidence of patients with severe acute pancreatitis were analyzed by Meta-analysis in homogeneity test and combined test in 6 studies. RESULTS： Homogeneity test showed that the cited studies of case fatality rates and complication incidence were homogeneous with X^2= 3. 156, X^2= 1.210, P 〉 0.05. In combined test, the combined OR = 3. 164, OR = 3.209 and its 95 % confidence interval was in 1. 390 - 7. 200 and 1.747 - 5. 900, respectively. CONCLUSION ： The ease fatality rates in combination group were significantly lower than those in single somatostain group. The efficacy of combination group was superior to that of single somatostain group.

关 键 词：META分析 生长抑素 生长激素 胰腺炎 联合治疗 病死率 并发症 

分 类 号：R969.4[医药卫生—药理学]